RETRACTED: Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial (Bone (2006) 39(5) (1080–1086)(S8756328206004443)(10.1016/j.bone.2006.04.025));Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial

Bone

Volumn 39, Issue 5, 2006, Pages 1080-1086

  Sato, Yoshihiro ^a   Honda, Yoshiaki ^a   Iwamoto, Jun ^b  

^a Mitate Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ETIDRONIC ACID; PLACEBO; PYRIDINOLINE;

ABDOMINAL PAIN; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOMALACIA; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 33749512176     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2017.10.008     Document Type: Erratum

References (41)

1. Bensimon G., Lacomblez L., Meininger V., and and the ALS/Riluzole Study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330 (1994) 585-591
2. Hayashi H., and Oppenheimer E.A. ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications. Neurology 61 (2003) 135-137
3. Gelanis D.F. Respiratory failure or impairment in amyotrophic lateral sclerosis. Curr Treat Options Neurol 3 (2001) 133-138
4. Lechtzin N., Rothstein J., Clawson L., Diette G.B., and Wiener C.M. Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler Other Motor Neuron Disord 3 (2002) 5-13
5. Gresham L.S., Molgaard C.A., Golbeck A.L., and Smith R. Amyotrophic lateral sclerosis and history of skeletal fracture: a case-control study. Neurology 37 (1987) 717-719
6. Kurtzke J.F., and Beebe G.W. Epidemiology of amyotrophic lateral sclerosis. 1. A case-control comparison based on ALS deaths. Neurology 30 (1980) 453-462
7. Sobue I., Tomita A., Takahashi K., and Imagawa T. Calcium studies in amyotrophic lateral sclerosis. Annual report of the research committee on motor neuron disease (1976), Ministry of Welfare of Japan, Tokyo 83-85
8. Yanagihara R., Garruto R.M., and Gajdusek D.C. Calcium and vitamin D metabolism in Guamanian Chamorrows with amyotrophic lateral sclerosis and Parkinson-dementia. Ann Neurol 15 (1984) 42-48
9. Sato Y., Honda Y., Asoh T., Kikuyama M., and Oizumi K. Hypovitaminosis D and decreased bone mineral density in amyotrophic lateral sclerosis. Eur Neurol 37 (1997) 225-229
10. Fleish H. Bisphosphonate: history and mechanism of action. Metab Bone Dis Relat Res 3 (1981) 279-287
11. Storm T., Thamsborg G., Steiniche T., Genant H.K., and Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322 (1990) 1265-1271
12. Harris S.T., Watts N.B., Jackson R.D., et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95 (1993) 557-567
13. Sato Y., Asoh T., Kaji M., and Oizumi K. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res 15 (2000) 2487-2494
14. World Federation of Neurology Subcommittee on Motor Neuron Disease. EI Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124 (1994) 98-107 [suppl.]
15. Appel V., Stewart S.S., Smith G., and Appel S.H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22 (1987) 328-333
16. Komar L., Nieves J., Cosman F., Rubin A., Shen V., and Lindsay R. Calcium homeostasis of an elderly population upon admission to a nursing home. J Am Geriatr Soc 41 (1993) 1057-1064
17. Matsumoto C., Kushida K., Yamazaki K., Imose K., and Inoue T. Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int 55 (1994) 324-329
18. Nakamura K., Nashimoto M., Okuda Y., Ota T., and Yamamoto M. Fish as a major source of vitamin D in the Japanese diet. Nutrition 18 (2002) 415-416
19. Demiaux B., Arlot M.E., Chapuy M.C., Meunier P.J., and Delmas P.D. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab 74 (1992) 1146-1151
20. Ramnemark A., Nyberg L., Borssén B., Olsson T., and Gustafson Y. Fractures after stroke. Osteoporos Int 8 (1998) 92-95
21. Grisso J.A., Kelsey J.L., Strom B.L., et al. The Northeast Hip Fracture Study Group. Risk factors for falls as a cause of hip fracture in women. N Engl J Med 324 (1991) 1326-1331
22. Sato Y., Kaji M., and Oizumi K. Vitamin D deficiency and the risk of hip fractures among disabled elderly stroke patients. Stroke 32 (2001) 1673-1677
23. Sato Y., Honda Y., Kaji M., Asoh T., Hosokawa K., Kondo I., et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 31 (2002) 114-118
24. Sato Y., Manabe S., Kuno H., and Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1α-hydroxyvitamin D3 in Parkinson's disease. J Neurol Neurosurg Psychiatry 66 (1999) 64-68
25. Massagli T.L., and Cardenas D.D. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 80 (1999) 998-1000
26. Hyman L.R., Boner G., Thomas J.C., and Segar W.E. Immobilization hypercalcemia. Am J Dis Child 124 (1972) 723-727
27. Cameron A., and Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. Curr Opin Clin Nutr Metab Care 5 (2002) 631-643
28. Peterlik M., and Cross H.S. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 35 (2005) 290-304
29. Patten B.M., and Engel W.K. Phosphate and parathyroid disorders associated with the syndrome of amyotrophic lateral sclerosis. In: Rowland L.P. (Ed). Human motor neuron disorders (1982), Raven Press, New York 181-200
30. Carnevale V., Minisola S., Romagnoli E., et al. Concurrent improvement of neuromuscular and skeletal involvement following surgery for primary hyperparathyroidism. J Neurol 239 (1992) 57
31. Thomas P., and Lebrun C. Progressive spastic paraparesis revealing primary hyperparathyroidism. Neurology 44 (1994) 178-179
32. Rodriguez G.E., Califano I.M., Alurralde A.M., Ercolano M., Silva M.C., and Sica R.E. Amyotrophic lateral sclerosis: its relationship with thyroid function and phosphate calcium metabolism. Rev Neurol 36 (2003) 104-108 [16-31]
33. Jackson C.E., Amato A.A., Bryan W.W., Wolfe G.I., Sakhaee K., and Barohn R.J. Primary hyperparathyroidism and ALS: is there a relation?. Neurology 50 (1998) 1795-1799
34. Siris E., Weinstein R.S., Altman R., et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81 (1996) 961-967
35. Miller R.G., Chretien K.C., Meoni L.A., Liu Y.P., Klag M.J., and Levine M.A. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 11 (2005) 2-7
36. Francis R.M., Boyle I.T., Moniz C., et al. A comparison of the effects of alfacalcidol treatment and vitamin D2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 6 (1996) 284-290
37. Lark R.K., Lester G.E., Ontjes D.A., et al. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr 73 (2001) 602-606
38. Sambrook P.N., Kotowicz M., Nash P., Styles C.B., Naganathan V., Henderson-Briffa K.N., et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18 (2003) 919-924
39. Chapuy M.C., Arlot M.E., Duboeuf F.D., et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327 (1992) 1637-1642
40. Guirguis-Blake J., and Phillips R.L. Oral vitamin D3 decreases fracture risk in the elderly. J Fam Pract 52 (2003) 431-435
41. Heikinheimo R.J., Inkovaara J.A., Harju E.J., et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51 (1992) 105-110